Abstract
Harrow Health Inc will release quarterly results on November 9, 2026 Post-Mkt, with the market looking for revenue of 98.47 million US dollars (+33.60% YoY), adjusted EPS of 0.23 (-13.17% YoY), and EBIT of 15.30 million US dollars (+2.65% YoY), while margin guidance remains undisclosed.
Market Forecast
Consensus points to a revenue print of 98.47 million US dollars, up 33.60% year over year, alongside adjusted EPS of 0.23, down 13.17% year over year; EBIT is projected at 15.30 million US dollars, an increase of 2.65% year over year, and management has not provided specific gross margin or net income guidance for this quarter. The company’s previously reiterated full-year revenue framework and the earnings setup suggest a quarter centered on revenue expansion and operating leverage progress, with near-term profitability shaped by commercial investments and integration costs.
Within the company’s main business, product sales remain the foundation, benefiting from broader channel reach and deepening prescriber adoption, and are positioned to continue growing with expanding portfolio breadth and improved account coverage. The most promising segment is product sales at 70.57 million US dollars last quarter, up 10.86% year over year, supported by expanding access, new prescriber uptake, and portfolio additions that can widen the revenue base.
Last Quarter Review
The previous quarter delivered revenue of 70.66 million US dollars (+10.86% YoY), a gross profit margin of 71.27%, GAAP net profit attributable to the parent company of -17.27 million US dollars, a net profit margin of -24.44%, and adjusted EPS of -0.46 (-453.85% YoY).
A notable financial highlight was a modest top-line beat of 0.32 million US dollars against consensus, while EBIT of -11.01 million US dollars underscored the impact of commercial investment and portfolio expansion costs on profitability. Main business activity centered on product sales of 70.57 million US dollars (+10.86% YoY), complemented by other revenue of 0.09 million US dollars, reflecting stable execution in the core revenue engine.
Current Quarter Outlook
Main business: product sales trajectory and quarter-on-quarter execution levers
Product sales remain the operative driver of this quarter’s revenue, and the key execution levers are expected to be breadth and depth of channel coverage, new-account acquisition, and improved pull-through from existing prescriber bases. The revenue consensus implies a substantial step-up versus the prior quarter, aligning with a broader portfolio that is scaling through expanded distribution relationships and increasing clinic-level adoption. Pricing discipline and balanced mix can help sustain a healthy gross profit profile, yet the path from revenue to EPS rests on how operating expenses trend as commercial teams execute across more call points. Operationally, this quarter’s setup emphasizes tighter inventory coordination with wholesalers and distributors to keep shipments aligned with end-user demand, while also supporting new product uptake without overextending working capital. The company’s 71.27% gross margin in the prior quarter provides a high base; the interaction of product mix, manufacturing yields, and any launch or relaunch costs will influence how gross margin trends relative to that baseline. If sell-through trends match the increased sell-in implied by guidance and consensus, product sales can retain momentum into year-end while offering a clearer view of operating leverage potential.
Most promising business: portfolio expansion centered on Tyrvaya nasal spray ramp
The completion of the Tyrvaya transaction adds a differentiated asset with clear strategic synergy to the commercial platform, and management has indicated expectations for more than 30.00 million US dollars in revenue next year from this product. In the near term, the contribution to this quarter will depend on the pace of relaunch activities, payer coverage progress, formulary wins, and the cadence of prescriber re-engagement under new ownership. Commercial integration typically elevates near-term operating expenses, but it also enables cross-selling and more efficient sampling and education programs across overlapping call points, which can expand the funnel for new patients. Given the company’s existing sales infrastructure, the ability to rapidly re-energize prescriber familiarity and streamline distribution should support steady quarter-on-quarter adoption as awareness scales. Importantly, consistent refill dynamics and adherence initiatives can amplify lifetime value metrics per patient, turning the early uptake curve into a more durable revenue stream. The net effect for this quarter is most likely a measured revenue contribution paired with opex investment, laying groundwork for higher revenue capture and margin expansion as the product cycles through onboarding, access wins, and prescriber habit formation.
Variables most likely to move the stock this quarter
The top-line result versus the 98.47 million US dollars consensus will be the primary directional catalyst, especially given the magnitude of the implied year-over-year increase; investors will parse whether growth is broad-based across the in-line portfolio or concentrated in a few assets. Margin trajectory relative to the 71.27% base from the prior quarter will matter, because it signals how product mix, cost of goods, and scale benefits trend as volume rises; even a stable gross margin can be a positive if operating expenses flatten sequentially and EBIT expands. The inflection in EPS, shifting from a loss last quarter to a positive adjusted EPS this quarter, is a key narrative pivot that can improve confidence in the earnings power of the model if achieved alongside solid revenue quality indicators (e.g., healthy reorder rates and normalized inventory). Investors will also watch for any updates to full-year revenue guidance and qualitative commentary on next-year contributions from portfolio additions, as guidance language often frames both near-term execution and medium-term confidence. Finally, any color on access wins, coverage tiering, and prescriber training progress for recently added assets can help investors calibrate the ramp, while commentary on opex discipline and integration costs will inform how quickly incremental revenue can translate into EBIT and EPS.
Analyst Opinions
Across collected views within the specified period, the tone is predominantly bullish, with a 100% positive skew among published ratings and target updates; notable voices include Lake Street (Buy, 60.00 US dollars target, analyst Thomas Flaten), B. Riley Securities (Buy, 60.00 US dollars target, analyst Mayank Mamtani), Craig-Hallum (Buy, 59.00 US dollars target, analyst Chase Knickerbocker), and an Outperform initiation by Leerink Partners with a 45.00 US dollars target. The common thread in these views is that the revenue engine is scaling through a broader portfolio, and that the commercial infrastructure can translate higher volumes into improving EBIT even as the company invests in integration and market development. Several analysts also emphasize the importance of product-level differentiation and the breadth of the promoted portfolio to support sustained prescription growth and account penetration, which reinforces confidence in the 98.47 million US dollars top-line forecast for this quarter. With last quarter’s numbers already demonstrating a resilient gross profit margin of 71.27% and with consensus calling for positive adjusted EPS this quarter, the majority view is that revenue growth will remain constructive and that earnings inflection is a credible near-term objective.
From a modeling perspective, bullish analysts generally frame this quarter as a test of operating leverage: they expect reported revenue to align with the high-30s year-over-year growth trajectory and for profitability metrics to improve sequentially as integration costs are absorbed and commercialization activities yield stronger sell-through. Their targets imply confidence that full-year revenue guidance can be achieved and that the expanded portfolio can carry momentum into the next fiscal year, particularly as newer assets contribute incrementally. The emphasis on uptake metrics, access progress, and patient persistence reflects an expectation that quarter-to-quarter variability in operating expenses will give way to steadier margin gains once the larger commercial footprint is fully utilized. In summary, the consensus majority expects this quarter to mark a constructive step on both revenue scale and earnings trajectory, underpinning the positive stance heading into the print and subsequent guidance commentary.Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments